PHD2/3 deletion significantly enhances T-cell activation and effector functions, improving the therapeutic responses to adoptive T-cell transfer in tumor-bearing mice, in various models, including the challenging autochthonous TiRP melanoma model. This evidence concerns the gene EGLN1 and melanoma.